AACR 2026 | The future of anti-CCR8 antibodies in solid tumor oncology
Bruno Bockorny, MD, Beth Israel Deaconess Medical Center, Boston, MA, comments on the development of anti-CCR8 therapies, highlighting the supportive data for the ongoing development of denikitug as a monotherapy and in combination with checkpoint inhibitors or chemotherapy in selected tumor types. Several clinical trials are underway, including a first-in-human trial of denikitug plus anti-PD-1 (NCT05007782). This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so anti-CCR8 fields are becoming very active. There are multiple programs in development. I think the data we generated and reported are supportive of the ongoing development of denikitug, both as a monotherapy and in combination with checkpoint inhibitors or chemotherapy in selected tumor types. I’ll highlight three separate efforts. One, we did include the denikitug and anti-PD-1 in this first-in-human trial, and we are still collecting the data...
Yeah, so anti-CCR8 fields are becoming very active. There are multiple programs in development. I think the data we generated and reported are supportive of the ongoing development of denikitug, both as a monotherapy and in combination with checkpoint inhibitors or chemotherapy in selected tumor types. I’ll highlight three separate efforts. One, we did include the denikitug and anti-PD-1 in this first-in-human trial, and we are still collecting the data. The results of the Nikita plus anti-PD-1 will be reported later. And there are actually two global phase two clinical trials that are being initiated. One in microsatellite-stable colorectal cancer, where the denikitug is going to be investigated as a monotherapy or combined with anti-PD-1 and standard of care chemotherapy. And the second phase two clinical trial will be in upper GI cancers, also the denikitug as a monotherapy or combined with anti-PD-1 and standard of care chemotherapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
